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Mesenchymal stem cells (MSCs) have been used in cell-based therapy in various disease conditions such as graft-versus-host
and heart diseases, osteogenesis imperfecta, and spinal cord injuries, and the results have been encouraging. However, as MSC
therapy gains popularity among practitioners and researchers, there have been reports on the adverse eﬀects of MSCs especially
in the context of tumour modulation and malignant transformation. These cells have been found to enhance tumour growth and
metastasis in some studies and have been related to anticancer-drug resistance in other instances. In addition, various studies have
also reported spontaneous malignant transformation of MSCs. The mechanism of the modulatory behaviour and the tumorigenic
potential of MSCs, warrant urgent exploration, and the use of MSCs in patients with cancer awaits further evaluation. However, if
MSCs truly play a role in tumour modulation, they can also be potential targets of cancer treatment.
1.Introduction
Mesenchymal stem cells (MSCs) are a group of heteroge-
neous multipotent cells which can be isolated from many
tissues throughout the body. The discovery of mesenchymal
stem cells can be dated back to the 1960s [1]. In recent years,
MSCs have gained popularity among stem cell researchers
due to their ability to self-renew and diﬀerentiate into many
diﬀerent cell types particularly cells of mesodermal origin
such as osteoblasts, chondrocytes, and adipocytes in culture
[2–4]. MSCs have also been reported to transdiﬀerentiate
into cells of ectodermal [5]a n de n d o d e r m a l[ 6, 7] origins.
Besides, MSCs have been applied clinically in patients with
severe dilated cardiomyopathy, cartilage disorders, stroke,
and autoimmune diseases with very encouraging results
[8–11]. However, despite the many potential therapeutic
beneﬁts of MSCs, the use of these cells has been reported to
bring adverse eﬀects such as an increased recurrence rate of
cancer, particularly haematological malignancies. There has
been increasing evidence regarding the tumour modulatory
eﬀect of MSCs, and it has been shown that MSCs may
enhance tumour growth in several studies [12–14]. Besides,
MSCs have also been demonstrated to undergo spontaneous
malignanttransformationinvitro[15]. This review therefore
gives an overview of the beneﬁts as well as the harmful eﬀects
of MSCs with an emphasis on the clinical implications of the
use of these cells.
2. What Are Mesenchymal Stem Cells?
The discovery of MSCs can be credited to the work done
by A. J. Friedenstein as early as the 1960s during which he
observed that the bone marrow is a source of stem cells for
mesenchymal tissues in postnatal life [16]. After harvesting
bone marrow samples from the iliac crest, Friedenstein
and his coworkers plated the suspension on plastic culture
dishes. They observed that upon gradual removal of the
haematopoeitic counterpart, there existed a population of
plastic-adherent, ﬁbroblast-like cells that could diﬀerentiate
into chondrocytes and osteoblasts and named them colony-
forming unit ﬁbroblasts [1, 17]. They were later renamed
mesenchymal stem cells due to their ability to diﬀerentiate
into cells of mesodermal origin [18].
However, it is worth mentioning that A. J. Friedenstein
was not the ﬁrst to propose the existence of stem cells. Prior
to his discovery of MSCs, works of several other scientists
have marked important milestones in stem cell research and
contributed to our current understanding of the important2 Journal of Biomedicine and Biotechnology
concepts of stem cells and diﬀerentiation. For instance,
Alexander A. Maximow was one of the ﬁrst to introduce
the idea of stem cells and their ability to diﬀerentiate into
other cell types in the context of haematopoiesis. Today,
much of our knowledge regarding haematopoiesis origi-
nated from Maximow’s proposal of the unitarian theory
of haematopoiesis in 1906 [19] which he conﬁrmed and
updated in his later works and proved that all blood cells
originated from a common mother cell [20].
On the other hand, two other scientists, Ernest A.
McCulloch and James E. Till were among the ﬁrst to demon-
strate the clonal nature of bone marrow cells through a
series of experiments involving bone marrow cell injection
into irradiated mice, during which they noticed the spleen
of these mice developed lumps or “spleen colonies” in
proportion to the number of marrow cells injected. They
then linked the observation to the possibility that these
colonies originated from a single marrow cell [21, 22].
It is now clear that there are at least two main types
of stem cells in the bone marrow—the haemopoietic stem
cells and the nonhaematopoietic MSCs. The latter has been
shown to be important in the proliferation, diﬀerentiation
a n ds u rvi v a lo fh a e m a t o po i eti cs t e mc e ll sin vitro [23]. Tradi-
tionallyMSCshavebeenisolatedfromthebonemarroweven
thoughbonemarrowMSCs(BM-MSCs)havebeenshownto
represent 0.001% of the whole marrow. Isolation of MSCs
from the bone marrow is primarily by adhesion to plastic
but these cells can also be concentrated by Percoll gradient
centrifugation [24]. While some evidence suggests that BM-
MSCs give rise to all mesenchymal lineages in distant tissues
[25, 26], these cells have been found to reside in marrow-
distant mesenchymal tissues such as skeletal muscles [27]
and adipose tissues [28]. Adipose-derived MSCs are found to
be similar to BM-MSCs but are easier to produce. These cells
have been reported to show a broader therapeutic capacity as
compared to BM-MSCs [29]. MSCs have also been located
in umbilical cord blood [30], dental tissues [31], synovial
ﬂuid [32], palatine tonsil [33], parathyroid gland [34]a n d
fallopian tube [35].
MSCs demonstrate heterogeneity in their morphology.
Various terms have been used to describe the appearance of
these cells, these include (1) ﬁbroblastoid cells, (2) giant fat
cells and blanket cells, (3) spindle shaped, ﬂattened cells, and
(4) very small round cells [36]. The morphology of these
cells also varies greatly with their seeding density, changing
dramatically especially when conﬂuence is reached in cell
culture condition. To this end, the relation between the
morphology and their cell functions remains unclear.
MSCs express a number of markers phenotypically.
However, none of them are speciﬁc to these cells. According
to the International Society for Cellular Therapy, human
MSCs under standard culture conditions must satisfy at
least three criteria: (1) they must be plastic-adherent; (2)
they must express C105, CD73 and CD90 and not CD45,
CD34, CD14, CD11b, CD79 or CD19 and HLA-DR surface
molecules by ﬂow cytometry; (3) they must be capable of
diﬀerentiating into osteoblasts, adipocytes and chondrob-
lasts [37]. However, this set of criteria is not deﬁnitive as
the expression of cell surface markers can be inﬂuenced
by extrinsic factors such as those secreted by accessory
cells in the initial passages and it is important to note
that in vitro expression of cell surface markers may not
correlate with in vivo expression [38]. Other markers that
are generally accepted include CD44, CD71, Stro-1, and
adhesion molecules such as CD 106, CD166, and CD29 [39].
3. The “Angelic” Side of Mesenchymal
Stem Cells
The multilineage diﬀerentiation potential is the hallmark of
MSCs. One of the criteria a cell has to satisfy before being
regarded as an MSC would be its ability to diﬀerentiate into
bone, cartilage, and fat cells [37]. However, studies have
shown that MSCs can be diﬀerentiated into other cells such
asskeletalcells,cardiomyocytes,endothelial,smoothmuscle,
and neural cells [40]. There have also been several studies
on the transdiﬀerentiation of MSCs into pancreatic beta cells
[6,41].However,theabilityofMSCstodiﬀerentiateintocells
of all three germ layers must be carefully examined as they
have been reported to spontaneously express neural markers
even in the undiﬀerentiated state [42].
MSCs are immune privileged cells. The fact that MSCs
fromchildrencanpersistinmothersfordecadessuggeststhat
these cells can escape immune surveillance for a long period
of time [43]. The immune phenotype of MSCs is generally
described as major histocompatibility (MHC) I positive and
MHCIInegative. Theyalsolackthecostimulatory molecules
CD40, CD80, and CD86. Although expressing low levels
of MHC I antigens can activate T cells, the absence of
costimulatory molecules cannot initiate secondary signals,
thus leaving the T cells anergic [44]. Besides, the expression
of low levels of MHC I is important in protecting MSCs from
natural killer cell-mediated cytotoxicity. On the other hand,
cells that do not express MHC I are targeted and destroyed
[45].
Today, a search of clinical trials at http://www.clinical-
trials.gov (a registry of federally and privately supported
clinical trials conducted in the United States and around the
world)usingthekeywords“mesenchymalstemcells”returns
morethanahundredresults.Themanypotentialtherapeutic
uses of MSCs have been related to their multipotent dif-
ferentiation capacity and unique immunological properties
mentioned. However, there are many other reasons why
MSCs have gained the interest of researchers in cell-based
therapy and tissue engineering. Firstly, MSCs are relatively
easy to obtain and maintain compared to other types of stem
cells such as embryonic stem cells. BM-MSCs can be readily
harvested from the iliac crest, cryopreserved, and expanded
many times in vitro to increase the number of transplantable
cells. It has been shown that these cells could be extensively
expanded in vitro up to 15 population doublings [46]w i t h
minor spontaneous diﬀerentiation during ex vivo expansion
[4]. Other than their ability to diﬀerentiate into cells of both
mesodermal and nonmesodermal origins, these cells are also
immunosuppressive [47]. Besides, MSCs also demonstrate
trophic eﬀects via the production of various growth factors
and cytokines [48]. Therefore, they have been used forJournal of Biomedicine and Biotechnology 3
the purposes of cell replacement, repair and regeneration,
immunomodulation, and disease modeling.
Manyinvestigationsonthefeasibilityoftheclinicaluseof
MSCshavemushroomedinthe1990s.However,Lazarusand
colleagues were among the ﬁrst to inject autologous cultured
MSCs into human subjects intravenously and assessed their
safety for cell-based therapy. It was demonstrated that
the infusion of autologous MSCs into 15 human subjects
with haematological malignancies was a safe treatment with
complete remission [49]. Subsequently, MSCs were used
in many other clinical trials to treat various diseases. For
examples, Horwitz et al. had used MSCs in the treatment of
children suﬀering from osteogenesis imperfecta. The study
showed engraftment of MSCs and improvement in these
children with a reduced frequency of bone breakages [50].
Besides, MSCs have also been used in clinical trials for
the treatment of inﬂammatory and heart diseases, as well
as spinal cord injuries. In 2004, Le Blanc et al. reported
successful treatment of steroid-refractory grade IV acute
graft-versus-host disease (aGVHD) in a 9-year-old boy
[51]. Later in a more recent clinical trial, Le Blanc et al.
demonstrated that 6 out of 8 patients with steroid-refractory
grade III-IV acute GVHD had complete disappearance of
GVHD with the infusion of MSCs [52]. MSCs have also been
used in ischaemic cardiomyopathy with promising results
[53]. However, the beneﬁts of MSC treatment may be due
to paracrine eﬀects of MSCs instead of their capacity to
diﬀerentiate into cardiomyocytes after injection. It has also
been demonstrated that the use of BM-MSCs together with
granulocyte macrophage colony-stimulating factors (GM-
CSF) improved acute and subacute spinal cord injuries.
However, such improvement was not observed in chronic
cases of spinal cord injuries [54].
Of particular interest, adipose tissue-derived MSCs or
adipose tissue-derived stem cells, ASDCs have gained much
popularity lately. Like MSCs of other origins, ASDCs, have
been shown to diﬀerentiate into various cell types such as
adipogenic, chondrogenic, osteogenic, myogenic cells, and
cells that adopt a pancreatic phenotype [55, 56]. The list of
potential clinical applications using ADSCs is exhaustive. To
name a few, disease conditions in which these cells may be
useful or potentially useful include intervertebral disc repair,
spinal cord injury, stroke, diabetes mellitus, rheumatoid
arthritis, and wound healing and repair [57]. ADSCs have
also been used in several clinical trials. For example, in a
phaseIIclinicaltrialbyGarcia-Olmoetal.,expandedADSCs
were used in the treatment of complex perianal ﬁstula either
of crytoglandular origin or associated with Crohn’s disease.
The study concluded that the use of ADSCs in combination
with intralesional ﬁbrin glue treatment achieved higher
healing rates than using ﬁbrin glue alone [58]. On the other
hand, Fang et al. demonstrated that the use of adipose
tissue-derived MSCs successfully suppressed hepatic graft-
versus-host disease (GVHD) in a 43-year-old woman after
allogeneic haematopoietic stem cell transplantation [59]a n d
the successful treatment of two children with acute GVHD
d u et oa l l o g e n e i cs t e mc e l lt r a n s p l a n t a t i o nf r o mH L A -
mismatched unrelated donors [60]. Other published human
trials include the use of adipose tissue-derived MSCs in
the treatment of traumatic calvarial defect [61] and urinary
incontinence [62].
Another type of MSCs, the muscle-derived MSCs (or
muscle-derived stem cells, MDSCs), has also gained much
attention recently. Although MSCs can be obtained from
the bone marrow, the biopsy procedure is more painful and
invasive in comparison to skeletal muscle biopsy, which can
be done using a small caliber needle under local anesthesia.
Therefore, MDSCs are preferred over BM-MSCs in several
studies. Some clinical applications or potential applications
includetheuseofMDSCsinmusculoskeletalmusclediseases
[63] and urinary incontinence [64].
4. The “Demonic” Side of
Mesenchymal Stem Cells
Despite the many potential therapeutic beneﬁts of MSCs,
these cells have been found to have various adverse eﬀects,
especially in the context of their direct and indirect involve-
ment in cancer. Basically, the role of MSCs in cancer can
be divided into (1) indirect involvement via the tumour
modulatory eﬀect of MSCs and (2) direct involvement via
malignant transformation of the MSCs themselves.
4.1. Tumour Modulatory Eﬀect of Mesenchymal Stem Cells.
There has been a constant debate on the role of MSCs
in tumour modulation. A few studies have supported that
M S C sm a ys u p p r e s st u m o u rg r o w t h[ 65–67] while others
believe that MSCs may contribute to tumour protection
via antiapoptotic eﬀect, tumour progression, metastasis, and
drug-resistance of cancer cells [12–14, 68–75]. Although
many have demonstrated an antiproliferative eﬀect exerted
by MSCs in cancer cells, the set back is that such eﬀect is
often accompanied by an antiapoptotic eﬀect. For instance,
Ramasamy et al. reported that MSCs inhibited proliferation
and apoptosis of tumour cells of haemopoeitic and non-
haemopoeitic origins, which was related to a transient arrest
of the tumour cells in G1 phase of the cell cycle in vitro.
On the other hand, when tumour cells were injected with
MSCs in vivo, the former demonstrated a faster growth when
comparedtoinjectionoftumourcellsalone[12].Theﬁnding
was supported by another study by Wei et al. who reported
that BM-MSCs from leukaemia patients inhibited growth
and apoptosis in serum-deprived K562 cells in vitro [69].
Interestingly, Li et al. reported that human MSCs played
a dual role in tumour cell growth in vitro and in vivo.I t
was found that human MSCs inhibited the proliferation of
A549 (lung cancer) and Eca-109 (esophageal cancer) cell
lines and caused G1 phase cell cycle arrest and apoptosis in
vitro. However, human MSCs were also found to enhance
tumour formation and growth in vivo [70]. The tumour
protective eﬀect of MSCs was also observed in melanoma
A375 cells but was absent in glioblastoma 8MGGBA cells as
described by Kucerova et al. [71]. Moreover, MSCs have also
been found to protect breast cancer cells through regulatory
T cells [14], prevent apoptosis of acute myeloid leukaemia













Figure 1: Indirect involvement of mesenchymal stem cells in cancer through tumour modulatory and other eﬀects.
exert antiapoptotic eﬀect in U266 and H929 melanoma cells
mediated by upregulation of survivin [13].
Besides preventing apoptosis and enhancing tumour
growth, MSCs have also been related to the promotion
of metastasis. Recent evidence suggests that MSCs could
migrate towards primary tumours and metastatic sites [76].
Chemokines secreted by MSCs have been shown to enhance
the emergence of pulmonary metastases and such secretion
has a strong interaction between breast cancer cells and
MSCs [72]. In addition, MSCs have also been found to play
a role in drug resistance in various cancer cells. Kurtova
et al. showed that MSCs protect chronic lymphocytic
leukaemic cells from ﬂudarabine-, dexamethosone-, and
cyclophosphamide-inducedapoptosis[74].Linetal.demon-
strated that BM-MSCs not only modulated the proliferation
of U937 but also the response of U937 cells to daunoblastina
and that Bcl-XL apoptosis inhibiting gene may be important
in determining the sensitivity of leukaemic cells to treatment
[73]. In another study, Vianello et al. showed that BM-
MSCs nonselectively protected chronic myeloid leukaemia
cells from imatinib-induced apoptosis. It was proposed that
theeﬀectwasmediatedviatheCXCR4/CXCL12axisandthat
the disruption of this axis could restore the leukaemic cells’
sensitivity to imatinib [75].
Another tumour enhancing property of MSCs is their
ability to suppress the immune system [47]. While this
immunosuppressive property of MSCs is good news to
patients with immune disorders, it is indeed a double-
edged sword, causing harm to those with cancer, as a
suppressed immune system may encourage tumour growth.
In addition, MSCs have been shown to migrate to the
t u m o u rs t r o m aa n dr e s u l t e di ne n h a n c e dt u m o u rg r o w t h
and metastasis. For example, Shinagawa et al. reported that
MSCs moved toward and interacted with tumour stroma of
colon cancer cells. They also diﬀerentiated into carcinoma-
associated ﬁbroblasts and promoted angiogenesis, tumour
growth, migration, invasion, and metastasis [77]. Figure 1
gives a summary of the indirect involvement of MSCs in
cancer via their tumour modulatory and other eﬀects.
4.2. Malignant Transformation of Mesenchymal Stem Cells.
The involvement of MSCs in cancer is not restricted to their
ability to enhance proliferation of cancer cells and to cause
drug-resistance in various cancer cell types via antiapoptotic
and other mechanisms. The MSCs themselves have also
been reported to contribute to malignant transformation in
several studies. Malignant transformation of MSCs used in
cell-based therapy can take place under three conditions:
(1) during in vitro expansion of MSCs, (2) malignant
transformation as a result of MSC interaction with the
tumour stroma, and (3) genetic manipulation of MSCs
which turn these cells cancerous (Figure 2).
In order to produce enough MSCs for clinical use,
massive in vitro expansion is often necessary. This in turn
renders MSCs susceptible to malignant transformation. In
2005, Rubio et al. ﬁrst reported that adipose tissue-derived
MSCs could immortalize and transform spontaneously as
a result of long-term in vitro expansion [15]. This was
followed by the demonstration of chromosomal instability
in long-term cultures of MSCs in later studies [78, 79].
Subsequent molecular characterization of MSC malignant
transformation by Rubio et al. demonstrated that these
c e l l sw e r ea b l et ob y p a s ss e n e s c e n c eb yu p r e g u l a t i n gc - m y c
and repressing p16 levels. These cells were also shown to
bypass cell crisis through acquisition of telomerase activity,
InK4a/Arf locus deletion, and Rb hyperphosphorylation. In
addition, modulation of mitochondrial metabolism, DNA
damage-repair proteins, and cell cycle regulators were also
found to play a role in malignant transformation [80].
Besides, it was also reported that alterations in the p21/p53
pathway resulted in MSCs bypassing senescence in vitro
with the generation of tumours resembling mesenchymal
sarcomas in vivo. The study concluded that a single mutation
was insuﬃcient to cause malignant transformation and
that such transformation was a result of multiple genetic
alterations [81]. In addition, malignant transformation of
MSCs has also been demonstrated in vitro by indirect
evidence of the derivation of malignant populations from
in vitro culture of MSCs, suggesting that MSCs could be the
origins of various cancers [82, 83].
The homing eﬀect allows MSCs to migrate towards
tumour cells. This migration not only allows MSCs to
interact with the tumour stroma and enhance tumour
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Figure 2: Direct involvement of mesenchymal stem cells in cancer through malignant transformation.
transformation of MSCs at the tumour site [77]. Exposure of
MSC to local stroma environment of a tumour can lead to
diﬀerentiationofthesecellsintocancer-associatedﬁbroblasts
(CAF) or tumour-associated ﬁbroblasts (TAF) [84]. This
transformation of MSCs into CAF or TAF becomes an
important part of the tumour, contributing to ﬁbrovascular
network expansion and tumour progression as described by
Spaeth et al. [85].
Other than in vitro spontaneous transformation and
stroma-induced transformation, a third possible way MSCs
can also undergo malignant transformation is by genetic
manipulations. Genetic manipulations of MSCs either by
viral or nonviral transgene delivery methods have been
extensively explored in many studies for the purpose of
immortalizing MSCs for long-term cultures and mainte-
nance as well as for the treatment of various diseases such as
neurological, blood, vascular, musculoskeletal disorders, and
cancer(reviewedbyResieretal.,[86]).However,suchgenetic
manipulations are not without risks and disadvantages—
either the transgene may be tumorigenic or the insertion
of transgenes causes disruption to MSC’s genome and lead
to malignant transformation. Lessons from spontaneous
malignant transformation of MSCs in long-term cultures
show that immortalizing MSCs by genetic manipulations
may increase the oncogenic potential of these cells as MSCs
tend to accumulate chromosomal instability during long-
term cultures [79, 82]. Literature on the potential dangers
and tumorigenic capacity of genetically manipulated MSCs
is scarce and further exploration is necessary.
5. ClinicalImplications andFutureDirections
In conclusion, the implications of the clinical use of MSCs
are at least ﬁve-fold.
(1) The use of MSCs for disease treatment in general:
the vast number of clinical trials and the abundance
of published literature suggest that MSC treatment
is feasible. Ongoing translational research may bring
new hopes to suﬀerers of many diseases which can
lead to improvement or cure.
(2) The use of MSCs in noncancer patients: there should
be long-term followups of patients in this category
with respect to the incidence of cancer. While MSCs
have been shown to be useful or potentially beneﬁcial
in many pathological conditions, care must be taken
not to introduce cancer to patients who receive MSC
therapy years down the line.
(3) The use of MSCs in cancer patients: further explo-
ration of the use of MSCs in cancer patients, espe-
cially those with haematological malignancies and
those requiring MSCs for GVHD, is necessary. The
beneﬁts of treatment should outweigh the adverse
eﬀects that these cells could bring to the patient. This
is especially true if the patient is on chemotherapy
andtheinteractionsbetweenanticancer-drug-treated
cancer cells and MSCs need to be established.
( 4 )M S C sa sv e h i c l e so ft a r g e t e dt h e r a p y :i fM S C st r u l y
play a role in tumour modulation, the mechanisms
by which they exert their modulatory eﬀect should
bewellelucidated.Thisincludesinvestigationsonthe
signaling pathways or regulatory proteins involved in
the tumour modulatory behaviour of MSCs. On the
other hand, such tumour modulatory eﬀect of MSCs
can be viewed as a double-edged sword, that is, if
they are the cause of the problem, they could also be
the solution for being vehicles of targeted delivery of
anticancer drugs.
(5) Stricter control and safety measures in the produc-
tion of MSCs for cell-based therapy: taking into con-
siderationthatMSCscanturnmalignantasaresultof
long-term culture and genetic manipulation, there is
a need for stricter control in cell handling procedures
to minimize the risk of malignant transformation.6 Journal of Biomedicine and Biotechnology
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